CEACAM5(CEA) Chimeric Antigen Receptor (CAR): A Comprehensive Guide and Our Service & Product Introduction

CEACAM5 (Carcinoembryonic Antigen, CEA) Chimeric Antigen Receptor (CAR) technology has emerged as a core focus in solid tumor immunotherapy research and clinical translation, targeting CEACAM5-expressing tumor cells in various malignancies. As a professional provider of gene engineering tools, our company offers a comprehensive range of high-quality CEACAM5 (CEA) CAR expression plasmid vectors and personalized custom construction services. RGBiotech is dedicated to supporting researchers, biopharmaceutical enterprises, and clinical institutions in accelerating the development of CEACAM5-targeted immunotherapies. If you are interested in our CEACAM5 (CEA) CAR expression plasmid vectors or custom construction services, or need technical advice for your CEACAM5 (CEA) CAR research, please contact us at admin@rgbiotech.com. Our professional team will promptly respond to your inquiries, providing personalized solutions to meet your research needs. We look forward to cooperating with you to advance CEACAM5 (CEA) CAR technology and accelerate the development of innovative immunotherapies for CEACAM5-related solid tumors.

Our CEACAM5(CEA) CAR Expression Plasmid Vector Products and Custom Services

CEACAM5 (CEA) CAR technology is a rapidly growing field in solid tumor immunotherapy, with increasing demand for high-quality plasmid vectors and custom construction services. As a leading provider of gene engineering tools, RGBiotech offers a comprehensive range of CEACAM5 (CEA) CAR expression plasmid vectors and professional custom construction services, tailored to meet the diverse needs of researchers and biopharmaceutical companies. Our products and services are designed to accelerate CEACAM5 (CEA) CAR research and clinical translation, with strict quality control and full-cycle technical support.

Our CEACAM5 (CEA) CAR expression plasmid vectors cover all generations (1st to 5th) and feature diverse designs to support various research applications.
1) 1st Generation: CD3ζ only (basic activation signal, low persistence, suitable for preliminary antigen recognition studies);
2) 2nd Generation: CD3ζ + one co-stimulatory domain (CD28 or 4-1BB, enhanced activation and proliferation, ideal for in vitro studies);
3) 3rd Generation: CD3ζ + two co-stimulatory domains (CD28+4-1BB/OX40, improved in vivo persistence and anti-tumor activity, suitable for in vivo models);
4) 4th Generation (ARM CAR): CD3ζ + co-stimulatory domain + cytokine (IL-7/IL-15/IL-21, enhanced anti-tumor immunity and tumor infiltration, suitable for solid tumor research);
5) 5th Generation: CD3ζ + co-stimulatory domain + inhibitory checkpoint antagonist (PD-1/CTLA-4 blockade, overcoming T cell exhaustion, ideal for long-term disease control).

Product Features

Product Applications

Custom CEACAM5 (CEA) CAR Plasmid Vector Construction Services

Introduction of CEACAM5(CEA)

The CEACAM5 gene (official symbol: CEACAM5; HGNC ID: 1843; Gene ID: 1048; also known as CEA, CD66e) is located on human chromosome 19q13.2, spanning approximately 40 kb of genomic DNA. It belongs to the carcinoembryonic antigen (CEA) gene family, which is a subset of the immunoglobulin superfamily. The human CEACAM5 gene has a reference sequence of NM_004363.2, with a gene length of 2796 bp, encoding a 180 kDa glycoprotein composed of 60% carbohydrate and 40% protein. Multiple alternatively spliced transcript variants have been identified, producing different isoforms that play distinct roles in tumor progression and immune regulation. The gene’s 5’-flanking region contains conserved transcription regulatory elements that control its tissue-specific expression, with high evolutionary conservation across mammalian species.

CEACAM5 (CEA) is a glycosylphosphatidylinositol (GPI)-anchored transmembrane glycoprotein belonging to the immunoglobulin superfamily. Its structure consists of one N-terminal immunoglobulin-like V-type (IgV) domain, followed by six immunoglobulin-like C2-type (IgC2) domains, a short transmembrane domain, and a GPI anchor that tethers the protein to the cell membrane. The extracellular IgV domain is responsible for ligand binding and cell-cell adhesion, while the IgC2 domains contribute to protein stability. CEACAM5 exists as a homodimer on the cell surface, and its heavy glycosylation helps evade immune surveillance in tumor cells. The absence of an intracellular signaling domain means it exerts its functions through interactions with other cell surface receptors and downstream signaling molecules.

CEACAM5 (CEA) primarily functions as a cell adhesion molecule, mediating homotypic (CEACAM5-CEACAM5) and heterotypic (CEACAM5-other CEACAM family members) cell-cell interactions. In normal physiology, it plays a role in epithelial cell adhesion, mucosal barrier maintenance, and embryonic development, with expression tightly regulated after birth. In tumor cells, abnormal overexpression of CEACAM5 promotes tumor progression by enhancing cell adhesion, inhibiting apoptosis, suppressing differentiation, and facilitating tumor invasion and metastasis. Additionally, CEACAM5 interacts with immune cells (e.g., T cells, macrophages) to suppress anti-tumor immune responses, creating an immunosuppressive tumor microenvironment. It is also closely associated with CD133-positive colorectal cancer stem cells, contributing to tumor recurrence and drug resistance.

In normal adult tissues, CEACAM5 (CEA) expression is extremely low or absent, with minimal expression in the mucosal epithelia of the colon, rectum, stomach, and lung (primarily in goblet cells and epithelial cells). In contrast, it is widely overexpressed in various malignant tumors, making it a classic tumor-associated antigen (TAA). Specifically, CEACAM5 is overexpressed in approximately 90% of colorectal cancers (CRC), 70-80% of gastric cancers, 50-60% of pancreatic cancers, 25% of advanced non-squamous non-small cell lung cancers (NSCLC), and subsets of breast, ovarian, and colorectal cancer metastases. Its restricted expression in normal tissues and high overexpression in tumors make it an ideal target for targeted immunotherapy.

CEACAM5 (CEA) is closely associated with the development, progression, and prognosis of various solid tumors, as well as some inflammatory diseases.
1) Solid Tumors: The most well-established association is with colorectal cancer, where CEACAM5 overexpression correlates with advanced stage, lymph node metastasis, and poor prognosis. It is also a key marker for gastric cancer, pancreatic ductal adenocarcinoma (PDAC), NSCLC, breast cancer, and ovarian cancer, serving as a diagnostic and prognostic indicator.
2) Inflammatory Diseases: Abnormal CEACAM5 expression has been observed in chronic inflammatory conditions such as inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), and Helicobacter pylori-associated gastritis, where it contributes to mucosal inflammation and tissue damage.
3) Metastatic Diseases: CEACAM5 overexpression is a hallmark of metastatic tumors, particularly colorectal cancer metastases to the liver, lungs, and peritoneum, making it a target for treating advanced and metastatic disease.

Introduction of CEACAM5(CEA) Chimeric Antigen Receptor (CAR)

CEACAM5 (CEA) Chimeric Antigen Receptor (CAR) is a genetically engineered receptor designed to redirect immune cells (e.g., T cells, NK cells) to specifically recognize and eliminate CEACAM5-expressing tumor cells. By fusing the extracellular CEACAM5-binding domain (e.g., anti-CEACAM5 single-chain variable fragment (scFv)) with intracellular signaling domains, CEACAM5 (CEA) CAR-equipped immune cells achieve MHC-independent recognition of CEACAM5+ tumor cells, overcoming the immunosuppressive tumor microenvironment and providing a promising strategy for treating CEACAM5-positive solid tumors.

A typical CEACAM5 (CEA) CAR consists of three core components, optimized for solid tumor targeting.
1) Extracellular Antigen-Binding Domain: Usually a high-affinity anti-CEACAM5 scFv or CEACAM5 ligand, responsible for specific binding to the extracellular IgV domain of CEACAM5 on tumor cells. Fully human scFv domains are preferred to reduce immunogenicity and improve in vivo persistence.
2) Hinge and Transmembrane Domain: Derived from CD28 or CD8α, facilitating the stability of the CAR on the immune cell surface, reducing steric hindrance in the tumor microenvironment, and enabling efficient transmission of intracellular signals.
3) Intracellular Signaling Domain: Varies by CAR generation, including activation domains (CD3ζ) and co-stimulatory domains (CD28, 4-1BB, OX40, etc.), which regulate the activation, proliferation, persistence, and anti-tumor activity of CAR-engineered cells. Advanced designs may include hypoxia-responsive elements, cytokine fusions, or immune checkpoint antagonist domains to enhance efficacy in solid tumors.

Current Research Achievements of CEACAM5 (CEA) CAR

Approved Drugs of CEACAM5 (CEA) CAR

CEACAM5 (CEA) CAR Research Hotspots

CEACAM5 (CEA) CAR Research Difficulties & Challenges

References

Q: What is the difference between different generations of CEACAM5 (CEA) CARs, and how to choose the right one?
A: The main difference lies in the intracellular signaling domains. 1st generation CARs (CD3ζ only) are suitable for preliminary studies of CEACAM5 recognition but have low in vivo persistence and are prone to exhaustion. 2nd (CD3ζ + single co-stimulatory domain) and 3rd (CD3ζ + two co-stimulatory domains) generations are ideal for preclinical studies requiring enhanced cell activation and persistence, especially for in vivo models. 4th generation CARs (with cytokines) are suitable for solid tumor research to improve tumor infiltration and persistence, addressing the TME barrier. 5th generation CARs (with checkpoint antagonists) are designed to overcome T cell exhaustion, making them ideal for long-term disease control in advanced solid tumors. Choose based on your research goals (e.g., colorectal cancer vs. NSCLC, in vitro vs. in vivo studies) and cell type (T cells vs. NK cells).

Q: Which vector backbone is suitable for CEACAM5 (CEA) CAR-T cell preparation, and why?
A: Lentiviral vectors are the most commonly used backbone for CEACAM5 (CEA) CAR-T cell preparation, as they can transduce both dividing and non-dividing cells, integrate into the host genome for stable long-term CAR expression, and have low immunogenicity-critical for avoiding human anti-mouse antibody (HAMA) responses. Retroviral vectors are suitable for dividing cells (e.g., activated T cells) and are cost-effective for large-scale production. AAV vectors are ideal for transient or tissue-specific CEACAM5 CAR expression, with high safety and low integration risk. Non-viral plasmid vectors are suitable for in vitro studies or non-viral delivery systems (e.g., electroporation, LNP), reducing the risk of viral vector-related complications and lowering manufacturing costs-particularly for off-the-shelf therapies.

Q: How to ensure high CEACAM5 (CEA) CAR expression efficiency in target cells?
A: Several factors affect expression efficiency: 1) Choose a suitable promoter (EF-1α for stable long-term expression, CMV for strong transient expression, or hypoxia-responsive promoters for tumor-specific expression); 2) Optimize the CEACAM5 (CEA) CAR gene codons for the target cell type (e.g., human primary T cells) to enhance translation efficiency; 3) Use high-purity, low-endotoxin plasmids to avoid cytotoxicity that impairs cell viability and expression; 4) Select an appropriate delivery method (electroporation for primary T cells, lipofection for cell lines); 5) Ensure the vector has a suitable linker (2A or IRES) for co-expression of CAR and markers, avoiding interference between components.

Q: What are the key considerations for CEACAM5 (CEA) CAR plasmid vector storage and handling?
A: To maintain plasmid integrity and activity: 1) Store plasmids at -20°C or -80°C, avoiding repeated freeze-thaw cycles (aliquot into single-use portions to prevent degradation); 2) Thaw plasmids on ice and centrifuge briefly before use to ensure uniform concentration; 3) Avoid exposure to high temperatures, UV light, and RNase/DNase contamination, which can damage plasmid DNA; 4) For lentiviral/retroviral backbones, store the packaged virus at -80°C with cryoprotectants to maintain transduction efficiency; 5) Follow sterile procedures when handling plasmids for cell culture applications to prevent contamination that could invalidate experiments; 6) Lyophilized plasmids can be stored at ambient temperature for three months, facilitating transportation and short-term storage.

Q: Can your custom service design CEACAM5 (CEA) CAR vectors with specific modifications (e.g., hypoxia-responsive elements, bispecific design, cytokine fusion)?
A: Yes. Our custom service supports various modifications, including inserting hypoxia-responsive elements to enhance tumor-specific activation of CAR cells, fusing cytokines (IL-7, IL-15, IL-21) to improve in vivo expansion and persistence, and designing bispecific CARs (e.g., CEACAM5/CD44v6) to mitigate tumor escape. We can also include tumor-specific promoters to restrict CAR expression. Simply provide your modification requirements, and our team will design a tailored solution.

Q: How to verify the functionality of CEACAM5 (CEA) CAR plasmid vectors after purchase?
A: We recommend the following verification steps: 1) Sequence verification to confirm the plasmid sequence is correct, including the CEACAM5 (CEA) CAR gene, promoter, and markers; 2) Transfect HEK293T cells with the plasmid, then detect CEACAM5 (CEA) CAR expression via flow cytometry (using anti-CEACAM5 or anti-CAR antibodies) or fluorescence microscopy (if fluorescent markers are included); 3) Perform in vitro cytotoxicity assays using CEACAM5-expressing target cells (e.g., colorectal cancer cell lines, NSCLC cell lines) to verify the killing ability of CAR-transduced T/NK cells—including ADC-resistant cell lines if applicable; 4) Detect cytokine production (e.g., IFN-γ, IL-2) via ELISA to confirm CAR activation. Our QC report includes key verification data, and we can provide technical guidance for additional functional tests (e.g., tumor infiltration assays in 3D models).

Q: What is the difference between CEACAM5 (CEA) CAR-T and CEACAM5 (CEA) CAR-NK cells, and which is better for my research?
A: CEACAM5 (CEA) CAR-T cells have strong proliferation ability and long-term persistence, making them suitable for long-term disease control (e.g., advanced colorectal cancer, NSCLC) but may have higher risk of CRS and difficulty infiltrating solid tumors. CEACAM5 (CEA) CAR-NK cells have lower immunogenicity, no risk of graft-versus-host disease (GVHD), and rapid cytotoxicity, making them suitable for patients with compromised T cell function or acute advanced disease. They also have better penetration into solid tumors and lower CRS risk. However, CAR-NK cells have shorter in vivo persistence and may require repeated infusions. Choose based on your research focus (long-term control vs. rapid efficacy) and safety requirements (e.g., allogeneic vs. autologous therapy).

Q: How to reduce off-target effects of CEACAM5 (CEA) CAR-engineered cells?
A: Off-target effects can be reduced by: 1) Using highly specific extracellular binding domains that only recognize CEACAM5 on tumor cells; 2) Using hypoxia-responsive promoters or tumor-specific promoters to restrict CAR expression to tumor cells, avoiding expression in normal CEACAM5-low tissues; 3) Adding a suicide gene (e.g., iCasp9) to the vector to eliminate CAR-engineered cells if off-target toxicity occurs; 4) Designing bispecific CARs that target CEACAM5 and a tumor-specific antigen, enhancing specificity for malignant cells; 5) Optimizing CAR affinity to avoid cross-reactivity with other CEACAM family members expressed on normal cells.

References

Contact Us